These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 604625)

  • 1. Tetracycline fluorescence in uremic and primary hyperparathyroid bone.
    Teitelbaum SL; Hruska KA; Shieber W; Debnam JW; Nichols SH
    Kidney Int; 1977 Nov; 12(5):366-72. PubMed ID: 604625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aluminum on normal and uremic rats: tissue distribution, vitamin D metabolites, and quantitative bone histology.
    Chan YL; Alfrey AC; Posen S; Lissner D; Hills E; Dunstan CR; Evans RA
    Calcif Tissue Int; 1983 May; 35(3):344-51. PubMed ID: 6871765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrastructural evaluation of the effects of vitamin D and uremia on bone in the rat.
    Weisbrode SE; Capen CC; Nagode LA
    Am J Pathol; 1974 Aug; 76(2):359-76. PubMed ID: 4276472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral aluminum administration to uremic, hyperparathyroid, or vitamin D-supplemented rats.
    Drüeke T; Lacour B; Touam M; Basile C; Bourdon R
    Nephron; 1985; 39(1):10-7. PubMed ID: 3969185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization.
    Cournot-Witmer G; Zingraff J; Plachot JJ; Escaig F; Lefèvre R; Boumati P; Bourdeau A; Garabédian M; Galle P; Bourdon R; Drüeke T; Balsan S
    Kidney Int; 1981 Sep; 20(3):375-8. PubMed ID: 7300127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased bone apposition in primary hyperparathyroidism: measurements based on short interval tetracycline labeling of bone.
    Tam CS; Bayley A; Cross EG; Murray TM; Harrison JE
    Metabolism; 1982 Aug; 31(8):759-65. PubMed ID: 7098847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites.
    Mak RH
    Kidney Int Suppl; 1989 Nov; 27():S227-30. PubMed ID: 2699996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of oral aluminium salts on the bone of non-dialysed uremic patients.
    Heaf JG; Pødenphant J; Joffe P; Andersen JR; Fugleberg S; Braendstrup O
    Scand J Urol Nephrol; 1987; 21(3):229-33. PubMed ID: 3433024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal osteodystrophy.
    Teitelbaum SL
    Hum Pathol; 1984 Apr; 15(4):306-23. PubMed ID: 6370824
    [No Abstract]   [Full Text] [Related]  

  • 12. Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions.
    Melsen F; Mosekilde L
    Acta Pathol Microbiol Scand A; 1980 Mar; 88(2):83-8. PubMed ID: 7368937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships of static and kinetic histomorphometric features of bone.
    Teitelbaum SL; Bates M
    Clin Orthop Relat Res; 1980; (146):239-45. PubMed ID: 6989538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].
    Ritz E; Kreusser W; Boland R; Bommer J
    Klin Wochenschr; 1979 Oct; 57(19):1053-9. PubMed ID: 392179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone cell kinetics and function during experimental uremia.
    Kimmel D; Ritz E; Krempien B; Mehls O
    Metab Bone Dis Relat Res; 1981; 3(3):191-8. PubMed ID: 7347796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D-induced hypercalcemia in experimental renal failure.
    Weisbrode SE; Capen CC
    Nephron; 1977; 18(1):26-34. PubMed ID: 846625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
    Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
    Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological effects of vitamin D and its analogs on bone.
    Teitelbaum SL
    Am J Clin Nutr; 1976 Nov; 29(11):1300-6. PubMed ID: 998541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphometric analysis of skeletal response to vitamin D in uremic rats fed a low calcium diet.
    Weisbrode SE; Capen CC
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1979 Jun; 30(3):275-80. PubMed ID: 43007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.